Daniel M. Schmitt, President, CEO, and Director of Actuate Therapeutics, Inc., filed a Form 4 on October 29, 2026, disclosing the purchase of 140,844 shares of common stock and acquisition of 70,422 warrants on October 28, 2026, in connection with the company's public offering.

Key Highlights

  • Purchase transaction: Schmitt acquired 140,844 shares of common stock on October 28, 2026, at a price of $0.355 per share.
  • Warrant acquisition: Schmitt also received 70,422 detachable warrants to purchase common stock, issued for no additional consideration, at an exercise price of $0.45 per share.
  • Warrant terms: The warrants are immediately exercisable and expire five years from the issuance date of October 28, 2026, making the expiration date October 28, 2031.
  • Direct beneficial ownership following the transaction: Schmitt directly holds 442,560 shares of common stock.
  • Indirect holdings: Schmitt is trustee of four irrevocable trusts holding 564,071, 22,223, 22,223, and 22,223 shares, respectively, for a combined indirect holding of 630,740 shares.
  • Public offering connection: According to the filing, shares and warrants were acquired in connection with the issuer's public offering, with one warrant issued for every two shares purchased.

Schmitt's October 2026 Public Offering Participation at Actuate Therapeutics

According to the Form 4 filed with the SEC on October 29, 2026, Daniel M. Schmitt, who serves as President, CEO, and Director of Actuate Therapeutics, Inc. (NASDAQ:ACTU), purchased 140,844 shares of the company's common stock on October 28, 2026, at $0.355 per share. The filing indicates this purchase was made in connection with the issuer's public offering.

Alongside the share purchase, Schmitt acquired 70,422 detachable warrants to purchase common stock at an exercise price of $0.45 per share. The filing explains that for every two shares of common stock acquired in the public offering, one detachable warrant was issued for no additional consideration. These warrants are immediately exercisable and carry an expiration date of October 28, 2031, five years from the issuance date.

Following the reported transaction, Schmitt directly holds 442,560 shares. The filing also reports indirect holdings through four irrevocable trusts dated December 31, 2019, for which Schmitt serves as trustee: The Schmitt Family Irrevocable Trust holds 564,071 shares; The Andrew Schmitt Irrevocable Trust, The Anna Schmitt Irrevocable Trust, and The Edward Schmitt Irrevocable Trust each hold 22,223 shares. The 70,422 warrants are reported as directly owned. The filing was signed by Paul Lytle as attorney-in-fact on October 29, 2026.

What Was Disclosed

Schmitt's Form 4 discloses the acquisition of 140,844 shares at $0.355 and 70,422 warrants exercisable at $0.45 through October 28, 2031, all in connection with Actuate Therapeutics' public offering. Direct beneficial ownership following the transaction stands at 442,560 shares, plus indirect trust holdings.